SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-20-121009
Filing Date
2020-04-27
Accepted
2020-04-27 16:29:56
Documents
3
Period of Report
2020-06-17
Effectiveness Date
2020-04-27

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT d920369ddef14a.htm DEF 14A 348147
2 GRAPHIC g920369g02s35.jpg GRAPHIC 33318
3 GRAPHIC g920369g62v85.jpg GRAPHIC 26553
  Complete submission text file 0001193125-20-121009.txt   431965
Mailing Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016
Business Address 430 EAST 29TH STREET, SUITE 940 NEW YORK NY 10016 917-336-9310
Prevail Therapeutics Inc. (Filer) CIK: 0001714798 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38939 | Film No.: 20820451
SIC: 2836 Biological Products, (No Diagnostic Substances)